Abu Dhabi Health Delegation Concludes First China Mission to Advance AI and Precision Medicine Collaboration

The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the emirate, has concluded its inaugural health and life sciences mission to China, advancing priority areas of collaboration designed to accelerate the translation of scientific and technological innovation into better health outcomes. The mission brought Abu Dhabi’s health and life sciences ecosystem together with leading Chinese healthcare institutions, universities, and innovators through 32 meetings and site visits across Beijing, Shanghai, and Shenzhen.
Rather than focusing on technology exchange alone, discussions identified opportunities to connect China’s scientific, technological, and manufacturing capabilities with the Emirate’s integrated healthcare ecosystem, population-scale data and genomics, clinical infrastructure, and regulatory environment. Across engagements with biotechnology and pharmaceutical companies, the delegation explored opportunities to accelerate development and accessibility of next-generation treatments, with discussions spanning advanced cell therapies, biologics, drug discovery, and organoid-based research. The mission also examined how Abu Dhabi’s diverse patient population and genomic capabilities could support validation of therapies across different populations and help shorten the pathway from scientific discovery to patient access.
Through engagements spanning AI-native hospitals, surgical robotics, laboratory automation, advanced imaging, and brain-computer interfaces (BCI), discussions explored potential pathways for clinical evaluation, joint development, specialized training, and responsible technology adoption, including opportunities to move beyond individual AI applications toward connected healthcare intelligence across the patient journey. Precision oncology was another major focus, with engagements exploring how advanced molecular diagnostics, imaging, genomics, and AI could transform the cancer pathway from earlier screening and diagnosis through treatment selection and recurrence monitoring. Building on Abu Dhabi’s existing genomics and biobanking capabilities, engagements also explored opportunities to connect population-scale biological data with advanced multi-omics, AI, and research capabilities, with potential areas including deeper understanding of diseases affecting local populations, earlier identification of health risks, shorter diagnostic journeys for rare diseases, and development of more precise diagnostics and treatments.
H.E. Dr. Noura Khamis Al Ghaithi, Undersecretary of DoH, stated that shaping the future of healthcare requires health ecosystems to connect scientific discovery and evidence with effective implementation and access to care. Al Ghaithi noted that innovation alone cannot transform healthcare, and that China brings scientific, technological, and manufacturing capabilities while Abu Dhabi offers an integrated environment where innovation can be developed, validated, applied, and responsibly scaled. Al Ghaithi added that through this mission, the delegation has identified clear opportunities to combine these strengths across artificial intelligence, precision medicine, advanced therapies, and diagnostics.
